(-0.08%) 5 304.25 points
(-0.09%) 40 140 points
(-0.05%) 18 465 points
(-0.07%) $83.11
(-0.62%) $1.752
(0.73%) $2 254.80
(0.74%) $25.10
(0.21%) $923.00
(0.09%) $0.927
(0.11%) $10.85
(0.07%) $0.793
(-0.06%) $92.52
Live Chart Being Loaded With Signals
OliX Pharmaceuticals, Inc., a clinical stage biotechnology company, focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases...
Stats | |
---|---|
Today's Volume | 63 912.00 |
Average Volume | 131 249 |
Market Cap | 274.07B |
EPS | KRW0 ( 2024-03-15 ) |
Next earnings date | ( KRW0 ) 2024-05-09 |
Last Dividend | KRW0 ( N/A ) |
Next Dividend | KRW0 ( N/A ) |
P/E | 0 |
ATR14 | KRW25.83 (0.16%) |
Volume Correlation
OliX Pharmaceuticals,Inc Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
OliX Pharmaceuticals,Inc Correlation - Currency/Commodity
OliX Pharmaceuticals,Inc Financials
Annual | 2023 |
Revenue: | KRW17.06B |
Gross Profit: | KRW14.42B (84.52 %) |
EPS: | KRW-1 323.81 |
Q4 | 2023 |
Revenue: | KRW10.51B |
Gross Profit: | KRW9.84B (93.66 %) |
EPS: | KRW199.43 |
Q3 | 2023 |
Revenue: | KRW2.03B |
Gross Profit: | KRW1.36B (67.05 %) |
EPS: | KRW-345.96 |
Q2 | 2023 |
Revenue: | KRW2.28B |
Gross Profit: | KRW1.61B (70.61 %) |
EPS: | KRW-645.58 |
Financial Reports:
No articles found.
OliX Pharmaceuticals,Inc
OliX Pharmaceuticals, Inc., a clinical stage biotechnology company, focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases. The company's products pipeline includes OLX101 for skin scar; OLX102 for skin whitening; OLX103, an atopic dermatitis product; OLX104 for hair loss; OLX105, an anti-wrinkle product; and OLX106 for diabetic foot ulcer. Its products pipeline also comprise OLX301 for age-related macular degeneration retinal fibrosis; OLX304 for retinitis pigmentosa; OLX201 for lung fibrosis; OLX202 for asthma; OLX203 for influenza; OLX401 for neuropathic pain; OLX701 for liver fibrosis; and OLX701 for cancer immunotherapy. The company has a collaboration agreement with Théa to develop SiRNA therapeutics for ophthalmic diseases; and a research collaboration with PCI Biotech Holding ASA. OliX Pharmaceuticals, Inc. was founded in 2010 and is based in Suwon, South Korea.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators